Osteoporosis

osteoporosis

← back to Endocrinology

Summary

The 2023 ACP living guideline updates pharmacologic management of primary osteoporosis and low bone mass in adults. Bisphosphonates are recommended as first-line therapy in both postmenopausal females and males with osteoporosis, with denosumab as second-line for bisphosphonate intolerance. Anabolic agents (romosozumab or teriparatide) followed by a bisphosphonate are reserved for females at very high fracture risk, while estrogen, estrogen-progestin, and SERMs are not recommended for treatment of osteoporosis.

Current guideline: ACP 2023 Pharmacologic Treatment of Osteoporosis · download Anki sub-deck

Versions

  • 2023 · ACP — ACP 2023 Pharmacologic Treatment of Osteoporosis
  • 2020 · Endocrine Society — Endocrine Society 2020 Postmenopausal Osteoporosis Guideline
    • Read the guideline: html
  • 2020 · AACE/ACE — AACE/ACE 2020 Osteoporosis Guideline
    • Read the guideline: html
  • Bone Health & Osteoporosis Foundation — BHOF Clinician’s Guide
    • Read the guideline: html

Table of contents